<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="355">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156528</url>
  </required_header>
  <id_info>
    <org_study_id>2021080C</org_study_id>
    <nct_id>NCT05156528</nct_id>
  </id_info>
  <brief_title>Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, immunogenicity and safety of S.&#xD;
      Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in infants and children aged from 6 months to&#xD;
      5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 11, 2021</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 11, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy study of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine as assessed by protective rate</measure>
    <time_frame>30 day after each vaccination</time_frame>
    <description>Evaluate the protective rate for bacillary dysentery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21000</enrollment>
  <condition>Dysentery</condition>
  <condition>Shigellosis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine</intervention_name>
    <description>Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intramuscular dose contains 0.15~0.25 mg of aluminum ion</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants and children aged from 3 months to 5 years old;&#xD;
&#xD;
          -  The legal representative voluntarily agrees to participate in the study and signed the&#xD;
             informed consent form;&#xD;
&#xD;
          -  The legal representative voluntarily agrees to comply with the requirements of the&#xD;
             clinical study protocol, and they can participate in all planned follow-up;&#xD;
&#xD;
          -  Subjects who didn't immuned with attenuated live vaccine within 14 days and&#xD;
             inactivated vaccine within 7 days before vaccination;&#xD;
&#xD;
          -  Axillary temperature ≤37.0℃;&#xD;
&#xD;
          -  According to the medical history, physical examination and the judgment of the&#xD;
             researcher, it is determined that the subject is in good physical condition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous proven history of bacillary dysentery;&#xD;
&#xD;
          -  Subjects who are allergic to tetanus toxoid, and have any history of other vaccination&#xD;
             or drug allergy, or a fever above 39.5 ℃ after previous vaccination;&#xD;
&#xD;
          -  Within 3 days before vaccination, suffering from acute diseases or in the acute&#xD;
             episode of chronic disease or using antipyretic, analgesic and antiallergic drugs&#xD;
             (such as acetaminophen, ibuprofen, etc.);&#xD;
&#xD;
          -  Had severe bowel disease, and had symptoms such as diarrhea, abdominal pain, pus and&#xD;
             blood stool and other symptoms in the past 3 days;&#xD;
&#xD;
          -  With pathological jaundice confirmed by existing diagnosis;&#xD;
&#xD;
          -  History of thrombocytopenia or other coagulation disorders with definite diagnosis;&#xD;
&#xD;
          -  Known or suspected immunological deficiency (such as perianal abscess, which indicates&#xD;
             that infants may have immune deficiency), and received long-term (≥14 days)&#xD;
             immunosuppressive therapy (radiotherapy, chemotherapy, systemic glucocorticosteroids≥2&#xD;
             mg/kg/day, antimetabolic drugs and cytotoxic drugs) within half a year before&#xD;
             vaccination, or confirmed that the parents were HIV infected;&#xD;
&#xD;
          -  Received immunoglobulin / blood products treatment within 3 months before vaccination;&#xD;
&#xD;
          -  Severe congenital malformations (functional impairment of important organs), severe&#xD;
             malnutrition, developmental disorders and serious genetic diseases (such as severe&#xD;
             thalassemia);&#xD;
&#xD;
          -  Subjects with the following diseases:&#xD;
&#xD;
               1. Serious liver and kidney diseases, cardiovascular diseases, malignant tumors and&#xD;
                  other chronic diseases;&#xD;
&#xD;
               2. Diagnosis with infectious diseases such as tuberculosis, viral hepatitis and so&#xD;
                  on;&#xD;
&#xD;
               3. Severe asthma;&#xD;
&#xD;
               4. Systemic rash, dermatophyte, skin suppuration or blister;&#xD;
&#xD;
               5. History or family history of convulsion, epilepsy, encephalopathy, mental&#xD;
                  illness;&#xD;
&#xD;
          -  Planning to participate or currently participating in clinical trials of other&#xD;
             vaccines or drugs;&#xD;
&#xD;
          -  Any situation that the investigator believed may affect the study evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Du</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hezhou Center for Disease Control and Prevention</name>
      <address>
        <city>Hezhou</city>
        <state>Guangxi</state>
        <zip>542899</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianbiao Li</last_name>
      <phone>86-13635076356</phone>
      <email>309551925@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzhai Center for Disease Control and Prevention</name>
      <address>
        <city>Luzhai</city>
        <state>Guangxi</state>
        <zip>545699</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baowei Guang</last_name>
      <phone>86-0772-6812646</phone>
      <email>lzjkxmb@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanjiang Center for Disease Control and Prevention</name>
      <address>
        <city>Sanjiang</city>
        <state>Guangxi</state>
        <zip>545500</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xue Yang</last_name>
      <phone>86-13100499521</phone>
      <email>sjjkxmk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Center for Disease Control and Prevention</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangxi</state>
        <zip>542600</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guide Nong</last_name>
      <phone>86-13321645288</phone>
      <email>ngd006@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yongnian Center for Disease Control and Prevention</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <zip>056011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhimin Liu</last_name>
      <phone>86-19932006666</phone>
      <email>liuzhimin199@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yuanshi Center for Disease Control and Prevention</name>
      <address>
        <city>Yuanshi</city>
        <state>Hebei</state>
        <zip>051130</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Licheng Qi</last_name>
      <phone>86-13582332166</phone>
      <email>qilicheng@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panzhihua Center for Disease Control and Prevention</name>
      <address>
        <city>Panzhihua</city>
        <state>Sichuan</state>
        <zip>617000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Meixian Liu</last_name>
      <phone>86-18090406818</phone>
      <email>449048010@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zigong Center for Disease Control and Prevention</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <zip>643000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qun Li</last_name>
      <phone>86-18990086037</phone>
      <email>lqzgcdc@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fushun Center for Disease Control and Prevention</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <zip>643299</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongbin Hu</last_name>
      <phone>86-18990018665</phone>
      <email>418299275@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 12, 2021</last_update_submitted>
  <last_update_submitted_qc>December 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

